Moderna's stock rose about 6% following reports of a Hantavirus outbreak and the company's early-stage mRNA vaccine research targeting the virus. This surge extends Moderna's strong 2026 performance, with shares up 95% year-to-date, outperforming Pfizer and Novavax. The rally is driven by renewed retail interest and solid fundamentals, including a Q1 revenue beat and reaffirmed full-year guidance. Investors are also watching for the August 5 FDA decision on Moderna's seasonal flu vaccine, which could expand its commercial portfolio beyond COVID-19 products.
Moderna has partnered with FFF Enterprises to launch Moderna Direct, an improved eCommerce platform built on FFF's BioSupply® technology. This platform offers a streamlined, customized ordering experience for Moderna's customers, supporting direct-to...
Moderna announced positive 5-year follow-up results from its melanoma vaccine trial showing a 49% reduction in recurrence or death risk when combined with KEYTRUDA, confirming earlier findings. Despite this, Moderna's stock dropped 2.78% to $45.88. T...
